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Response

To the Editor:
We thank Drs Chang and Hancox for their interest in our work on natriuretic peptides in community-acquired pneumonia. 1 -4 The current report 1 extends our previous observations and tries to highlight fi ndings that (1) apply to the whole family of natriuretic peptides in general and (2) provide a direct comparison of the clinical potential of all three commercially available natri uretic pep tides (B-type natriuretic peptide [BNP] , N-terminal pro-B-type natriuretic peptide, and midregional pro-atrial natriuretic peptide ). In this analysis, we used the data from all patients who presented to our institution with community-acquired pneu monia in whom we had the measurements of all three natriuretic peptides available. As correctly mentioned by Drs Chang and Hancox, some of these patients were in earlier cohorts that dealt exclusively with BNP. About one-third of the patients were included in the recruitment period from April 2006 to March 2007.
Drs Chang and Hancox are also correct in highlighting that in some patients, physicians used procalcitonin levels as additional information for the tailoring of the duration of antibiotic treatment. Regarding blinding, physicians were blinded to N-terminal pro-B-type natriuretic peptide and midregional pro-atrial natriuretic peptide levels in all patients. These levels were measured from frozen samples long after the discharge of patients. The blinding regarding BNP levels was not uniform. In about one-half of the patients, BNP levels were measured in a blinded fashion; in the other half, BNP levels would have been available to physicians via the electronic patient records. 
Preventing VTE in Outpatients With Cancer
To the Editor:
We applaud the innovations pioneered by the American College of Chest Physicians evidence-based clinical practice guidelines on antithrombotic therapy and prevention of thrombosis (February 2012). However, we are concerned about the resulting recommendations regarding cancer-associated thrombosis, a signifi cant contributor to the public health burden of VTE and an area of particular interest to us.
Regarding prevention of VTE in nonsurgical patients, 1 the panel suggested that outpatients with solid tumors with additional risk factors for VTE should receive prophylactic-dose lowmolecular-weight heparin or low-dose unfractionated heparin (recommendation 4.2.2). Additional risk factors cited by the panel include hormonal therapy and angiogenesis inhibitors. In our opinion, this recommendation (even as a grade 2B) does not refl ect an appropriate interpretation of the results of recent studies on cancer thromboprophylaxis and risk assessment. If these recommendations were to be followed, tens of thousands of women with breast cancer or men with prostate cancer on hormonal therapy for extended periods would receive low-molecularweight heparin or low-dose unfractionated heparin. The rate of VTE in these patients, however, is much lower than other cancer subgroups, and there are no studies showing a benefi t of thromboprophylaxis. 2 Similarly, the linkage between antiangiogenic agents, such as bevacizumab, and VTE has not been consistently demonstrated in pooled analyses. 3 (Although thalidomideand lenalidomide-based regimens are associated with VTE, these are used primarily in myeloma and not solid tumors.) Recommendation 4.2.2 further fails to cite important risk factors, such as site of cancer, and a risk assessment model for chemotherapyassociated VTE that has been externally validated in multiple studies; both are the basis for recent and ongoing prophylaxis studies. 4 The Institute of Medicine's 2011 report, Clinical Practice Guidelines We Can Trust , emphasized guideline development group composition and external review. 5 Inclusion of oncology content experts on the panel or as external reviewers could have provided a different interpretation of the data and more clinically sound recommendations. We urge the panel to consider such multidisciplinary input for the next iteration of the guidelines. Even weak recommendations formulated without scientifi c evidence can have a negative impact on patient care and future study design. It is quite possible that institutional review boards may identify these suggestions as the standard of care, affecting future study feasibility. As physicians and researchers involved in this fi eld, we disagree with recommendation 4.2.2 and suggest that clinicians consider recommendations from cancer-focused guidelines, such as those of the American Society of Clinical Oncology and the National Comprehensive Cancer Network.
